Your browser is no longer supported. Please, upgrade your browser.
Settings
ACER Acer Therapeutics Inc. daily Stock Chart
ACER [NASD]
Acer Therapeutics Inc.
Index- P/E- EPS (ttm)-2.01 Insider Own24.21% Shs Outstand9.92M Perf Week0.90%
Market Cap234.21M Forward P/E- EPS next Y-2.03 Insider Trans- Shs Float7.57M Perf Month-5.56%
Income-17.00M PEG- EPS next Q-0.46 Inst Own59.10% Short Float1.78% Perf Quarter3.69%
Sales- P/S- EPS this Y83.90% Inst Trans0.36% Short Ratio4.95 Perf Half Y-23.29%
Book/sh5.81 P/B4.06 EPS next Y6.30% ROA-57.90% Target Price56.00 Perf Year26.66%
Cash/sh4.66 P/C5.07 EPS next 5Y- ROE-62.90% 52W Range16.02 - 34.10 Perf YTD17.35%
Dividend- P/FCF- EPS past 5Y56.90% ROI- 52W High-30.76% Beta2.61
Dividend %- Quick Ratio22.00 Sales past 5Y- Gross Margin- 52W Low47.38% ATR0.89
Employees6 Current Ratio22.00 Sales Q/Q- Oper. Margin- RSI (14)56.05 Volatility3.38% 3.58%
OptionableNo Debt/Eq0.00 EPS Q/Q19.50% Profit Margin- Rel Volume0.86 Prev Close23.87
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume27.26K Price23.61
Recom1.80 SMA20-0.87% SMA506.86% SMA2000.29% Volume23,548 Change-1.09%
Feb-15-19Resumed Raymond James Outperform $40
Dec-20-18Initiated Needham Buy $48
Feb-26-18Initiated ROTH Capital Buy
Dec-20-17Initiated H.C. Wainwright Buy $50
Jan-02-19 08:30AM  Acer Therapeutics Announces In-license of Osanetant from Sanofi GlobeNewswire +6.61%
Dec-26-18 04:09PM  Is This Biotech Stock Turning A Corner? Acer Pops On FDA Acceptance Investor's Business Daily +11.30%
08:30AM  Acer Therapeutics Announces FDA Acceptance of NDA and Priority Review for EDSIVO for the Treatment of vEDS GlobeNewswire
Dec-20-18 06:26AM  Opexa Therapeutics Enters Oversold Territory Zacks
Dec-17-18 08:30AM  Acer Therapeutics Appoints Salma Jutt as Chief Commercial Officer GlobeNewswire
Nov-09-18 04:01PM  Acer Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-18 08:30AM  Acer Therapeutics to Present at the Evercore ISI HealthConX Conference GlobeNewswire
Oct-29-18 08:30AM  Acer Therapeutics Submits NDA for EDSIVO for the Treatment of vEDS GlobeNewswire
Oct-09-18 01:46PM  Do Institutions Own Shares In Acer Therapeutics Inc (NASDAQ:ACER)? Simply Wall St.
Sep-24-18 08:30AM  Acer Therapeutics to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Aug-20-18 08:30AM  Acer Therapeutics to Present at the 20th Annual H.C. Wainwright Conference GlobeNewswire
Aug-16-18 04:01PM  HTG Molecular Appoints Michelle R. Griffin to its Board of Directors GlobeNewswire
Aug-13-18 04:01PM  Acer Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-18 04:01PM  Acer Therapeutics Announces Closing of Underwritten Public Offering GlobeNewswire
Aug-01-18 09:00AM  Acer Therapeutics Announces Pricing of Underwritten Public Offering GlobeNewswire +18.28%
Jul-31-18 04:01PM  Acer Therapeutics Announces Underwritten Public Offering GlobeNewswire -7.69%
05:40AM  Opexa Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-03-18 10:31AM  Acer Therapeutics (ACER) Shares March Higher, Can It Continue? Zacks
May-24-18 07:45AM  Report: Developing Opportunities within Opexa Therapeutics, Federated National Holding, Hess Midstream Partners LP, Zion Oil & Gas, Omnicell, and Gladstone Land Future Expectations, Projections Moving into 2018 GlobeNewswire
May-22-18 08:43AM  Why Opexa Therapeutics (ACER) Could Shock the Market Soon Zacks
May-14-18 04:01PM  Acer Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Apr-02-18 08:25AM  New Research Coverage Highlights TOCAGEN INC, Acer Therapeutics, DMC Global, The Providence Service, WEX, and Alexander's Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-07-18 04:01PM  Acer Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
Mar-06-18 08:30AM  Acer Therapeutics to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-05-18 08:30AM  Acer Therapeutics Expands Management Team with the Appointment of Three Executives and One New Key Hire GlobeNewswire
Feb-01-18 07:55AM  New Research: Key Drivers of Growth for Guess?, Acer Therapeutics, American National Insurance, J P Morgan Chase, Juno Therapeutics, and Allergan Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-31-18 08:30AM  Acer Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire
Jan-03-18 08:30AM  Acer Therapeutics to Present at the Biotech Showcase 2018 Conference GlobeNewswire +6.75%
Dec-27-17 04:01PM  Acer Therapeutics Announces Partial Exercise of Over-allotment Option in Public Offering GlobeNewswire
Dec-14-17 04:01PM  Acer Therapeutics Announces Closing of Underwritten Public Offering of Common Stock GlobeNewswire
Dec-12-17 09:00AM  Acer Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock GlobeNewswire -15.27%
Dec-11-17 04:01PM  Acer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
Nov-13-17 04:05PM  Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Oct-12-17 08:30AM  Acer Therapeutics Welcomes Two New Members to its Board of Directors GlobeNewswire +5.35%
Oct-05-17 08:30AM  Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer GlobeNewswire
Sep-25-17 08:30AM  Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome GlobeNewswire +10.89%
Sep-22-17 08:30AM  Acer Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Acer Therapeutics Inc., a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease. The company was founded in 2013 and is headquartered in Newton, Massachusetts.